Harmonic Discovery Announces Licensing Agreement with BioVentures and UCSF for FLT3 Mutated AML Development Program
The compound, named HD-10019, is currently in pre-clinical development and is expected to commence IND-enabling studies in late 2024.
- The compound, named HD-10019, is currently in pre-clinical development and is expected to commence IND-enabling studies in late 2024.
- HD-10019 is a type II kinase inhibitor that was rationally designed to overcome tyrosine kinase domain resistance mutations in the FLT3 kinase and improve myelosuppression versus standard of care agents for FLT3 mutated AML.
- "We are excited to work with BioVentures and UCSF and take a step forward in delivering a novel treatment to FLT3 mutated AML patients," said Rayees Rahman, PhD, CEO of Harmonic Discovery.
- Wilson Sonsini Goodrich & Rosati served as legal advisor to Harmonic Discovery on matters relating to the Licensing Agreement and related corporate and patent strategy matters.